A Prospective, Interventional, Randomized, Double-blind and Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bacillus coagulans LBSC in Subjects with Irritable Bowel Syndrome.

Advanced Enzymes Technologies Ltd0 个研究点目标入组 40 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Male and females aged 18 and 65 yrs. completed years (both inclusive) with diagnosis of IBS as per Rome IV criteria with following symptoms for more than 3 months
•2. Abdominal discomfort such as mild pain, cramping, bloating,
•3. Altered bowel habit indicated by frequent diarrhea or constipation
•4. Functional dyspepsia
•3. Written informed consent by study participants

•1. On antibiotics or laxatives within the preceding 6 weeks.
•2. Presence of inflammatory bowel disease
•3. Presence of acute GI tract infection
•4. Presence of fever, abdominal mass, signs of bowel obstruction
•5. History of colon cancer or diverticulitis
•6. Infection by human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus
•7. Patients with celiac disease defined by biopsy of the duodenal mucosa.
•8. History of scleroderma and gastroparesis
•9. Hypothyroidism

发起方

Advanced Enzymes Technologies Ltd